Stock Research for GALT

GALT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GALT Stock Chart & Research Data

The GALT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GALT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GALT Due diligence Resources & Stock Charts

The GALT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GALT Detailed Price Forecast - CNN Money CNN View GALT Detailed Summary - Google Finance
Yahoo View GALT Detailed Summary - Yahoo! Finance Zacks View GALT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GALT Trends & Analysis - Trade-Ideas Barrons View GALT Major Holders - Barrons
NASDAQ View GALT Call Transcripts - NASDAQ Seeking View GALT Breaking News & Analysis - Seeking Alpha
Spotlight View GALT Annual Report - CompanySpotlight.com OTC Report View GALT OTC Short Report - OTCShortReport.com
TradeKing View GALT Fundamentals - TradeKing Charts View GALT SEC Filings - Bar Chart
WSJ View Historical Prices for GALT - The WSJ Morningstar View Performance/Total Return for GALT - Morningstar
MarketWatch View the Analyst Estimates for GALT - MarketWatch CNBC View the Earnings History for GALT - CNBC
StockMarketWatch View the GALT Earnings - StockMarketWatch MacroAxis View GALT Buy or Sell Recommendations - MacroAxis
Bullish View the GALT Bullish Patterns - American Bulls Short Pains View GALT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GALT Stock Mentions - StockTwits PennyStocks View GALT Stock Mentions - PennyStockTweets
Twitter View GALT Stock Mentions - Twitter Invest Hub View GALT Investment Forum News - Investor Hub
Yahoo View GALT Stock Mentions - Yahoo! Message Board Seeking Alpha View GALT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GALT - SECform4.com Insider Cow View Insider Transactions for GALT - Insider Cow
CNBC View GALT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GALT - OTC Markets
Yahoo View Insider Transactions for GALT - Yahoo! Finance NASDAQ View Institutional Holdings for GALT - NASDAQ


Stock Charts

FinViz View GALT Stock Insight & Charts - FinViz.com StockCharts View GALT Investment Charts - StockCharts.com
BarChart View GALT Stock Overview & Charts - BarChart Trading View View GALT User Generated Charts - Trading View




Latest Financial News for GALT


New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
Posted on Tuesday November 27, 2018

NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.


Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
Posted on Monday November 19, 2018

NORCROSS, Ga., Nov. 19, 2018 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold.


Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
Posted on Tuesday November 13, 2018

Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its third fiscal quarter, which ended September 30, 2018, and provided a business update. Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “Our central focus remains advancing our plan for a Phase 3 clinical trial program with GR-MD-02 in NASH cirrhosis, for which we continue to make progress. Importantly, we have been collaborating with leading NASH experts who have been enlisted to help strengthen the overall plan.


Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options
Posted on Monday November 05, 2018

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.